WuXi Biologics (02269) plummeted 5.66% during Tuesday's intraday trading session. The steep decline came after the company announced it would sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million.
The divestment move appears to be a preemptive measure ahead of potential U.S. legislation that could restrict business for Chinese biotech companies. The U.S. House of Representatives passed the Biosecure Act in September, which would ban federal contracts with targeted firms and their business partners.
With growing concerns over potential U.S. sanctions, investors have become wary of WuXi Biologics' future prospects, leading to the sharp sell-off in the company's shares on Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。